Watchlist · 70/100Jul 20, 5:15 PM EDT
Gilead Downgraded on HIV PrEP Market Challenges
GILD
Leerink Partners downgraded Gilead Sciences (GILD) to market perform from outperform, citing headwinds in the HIV PrEP market. The price target was cut to $127 from $146, implying about 5% downside. This reflects concerns over slowing growth in the PrEP segmen…
- ▹Downgrade due to HIV PrEP headwinds, but Gilead's strong HIV franchise and diversified pipeline provide buffer.
- ▹Platform strength with multiple approved products and manufacturing capabilities offset commercial concerns.
Watchlist · 67/100Jul 20, 6:06 PM EDT
Krystal Biotech Added to S&P MidCap 400, Replacing Taylor Morrison Home
SPGIKRYSBRK.BTMHC
Krystal Biotech (KRYS) will join the S&P MidCap 400 index, replacing Taylor Morrison Home (TMHC) due to merger activity. This inclusion is a positive signal for KRYS, potentially increasing visibility and attracting index fund inflows, which could boost its st…
- ▹Index inclusion signals market validation and potential increased institutional ownership.
- ▹Krystal's gene therapy platform and commercial product (VYJUVEK) support technology and commercial scores.
Watchlist · 65/100Jul 20, 10:52 AM EDT
Dyne's Duchenne Drug Gets FDA Priority Review, January 2027 Action Date Set
DYNSRPT
Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen, a Duchenne muscular dystrophy treatment, with priority review and a January 21, 2027 action date. Approval would enable a launch, potentially competing with Sarepta's existing therapies.…
- ▹FDA acceptance with priority review for DMD treatment
- ▹Single-asset company with no other pipeline depth
Neutral · 57/100Jul 20, 10:29 AM EDT
4D Molecular's Single-Dose Wet AMD Therapy Shows Durable 2-Year Phase 2 Results
FDMTREGN
4D Molecular Therapeutics (FDMT) announced positive two-year data from the PRISM phase 2b trial of 4D-150, a single-dose gene therapy for wet age-related macular degeneration (AMD). The treatment maintained best corrected visual acuity and controlled central r…
- ▹Positive phase 2 data with durable effect supports potential for less frequent dosing
- ▹Single-asset micro-cap with no platform or manufacturing differentiation limits upside
High Risk · 37/100Jul 21, 7:54 AM EDT
OKYO Pharma Chairman Boosts Stake with $35K Share Buy
OKYO
OKYO Pharma chairman Gabriele Cerrone purchased 25,000 shares at $1.40 each via Panetta Partners, increasing his holdings to 10.85M shares (20.51% of total). Insider buying signals confidence in the company's prospects, which may positively influence investor…
- ▹Insider purchase shows confidence but no material business catalyst
- ▹Single-asset micro-cap with no recent regulatory or commercial news
High Risk · 32/100Jul 20, 4:57 PM EDT
Karyopharm Plunges 21% After Revealing Executive Retention Plan
KPTI
Karyopharm Pharmaceuticals (KPTI) shares fell 21% after disclosing a 2026 Leadership Cash Retention Program for top executives including the CEO, CFO, and chief medical officer. The plan raises concerns about management stability and cash allocation, signaling…
- ▹Retention plan signals potential leadership instability or cash burn concerns
- ▹Single-asset company with no recent positive catalysts
High Risk · 27/100Jul 20, 10:59 AM EDT
Immix Biopharma CMO Terminated After Arrest Following Two Decades as Fugitive
IMMX
Immix Biopharma (IMMX) shares fell ~13% after the company terminated Chief Medical Officer Richard Graydon, who was arrested after being on the run for 20 years. The sudden leadership change and negative publicity raise concerns about corporate governance and…
- ▹CMO arrest and termination severely damages credibility and narrative.
- ▹Single-asset micro-cap with no recent positive catalysts.